Jorine ’t Lam - Boer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jorine ’t Lam - Boer has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Johannes H. W. de Wilt
Department of Surgery, Radboud University Medical Centre, Nijmegen, The Netherlands
2 shared publications Miriam Koopman
Department of Surgery, Radboud University Medical Center, Nijmegen, The Netherlands
2 shared publications- Rob Henricus Andreas Verhoeven
Netherlands Comprehensive Cancer Organization (IKNL), Department of Research & Development, Utrecht, the Netherlands; Amsterdam UMC Location University of Amsterdam, Medical Oncology, Meibergdreef 9, Amsterdam, the Netherlands; Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands
2 shared publications - Anton F. J. de Haan
Department for Health Evidence, Section Biostatistics, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands
1 shared publication - Arjen M. Rijken
Department of Surgery, Amphia Hospital, Breda, Netherlands
1 shared publication - C. Al Ali
Department of Surgery, Amphia Hospital, PO Box 90157, 4800 RL Breda, The Netherlands
1 shared publication
Latest Publications
- 1 April 2017
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 265 (4) , e58-e59
Prognostic Relevance of Palliative Primary Tumor Removal
- 1 April 2017
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 265 (4) , e58-e59
Prognostic Relevance of Palliative Primary Tumor Removal
- 1 January 2017
- Published by Elsevier in European Journal of Cancer
- Vol. 71, 109-116
Regional and inter-hospital differences in the utilisation of liver surgery for patients with synchronous colorectal liver metastases in the Netherlands
- 1 January 2017
- Published by Elsevier in European Journal of Cancer
- Vol. 71, 109-116
Regional and inter-hospital differences in the utilisation of liver surgery for patients with synchronous colorectal liver metastases in the Netherlands
- Open Access
- 24 June 2016
- Published by Wiley in International Journal of Cancer
- Vol. 139 (9) , 2082-2094
Palliative resection of the primary tumor is associated with improved overall survival in incurable stage IV colorectal cancer: A nationwide population‐based propensity‐score adjusted study in the Netherlands
As the value of palliative primary tumor resection in stage IV colorectal cancer (CRC) is still under debate, the purpose of this population‐based study was to investigate if palliative primary tumor resection as the initial treatment after diagnosis was associated with improved overall survival. All patients with stage IV colorectal adenocarcinoma (2008–2011) were selected from the Netherlands Cancer Registry, and patients undergoing treatment with curative intent (i.e., metastasectomy, radiofrequency ablation and/or hyperthermic intraperitoneal chemotherapy), or best supportive care were excluded. After propensity score matching, a multivariable Cox proportional hazard model was performed to determine the association between treatment strategy and mortality. From a total group of 10,371 patients with stage IV CRC, 2,746 patients (26%) underwent an elective palliative resection of the primary tumor, whether or not followed by systemic therapy, and 3,345 patients (32%) were initially treated with palliative systemic therapy. After propensity score matching, median overall survival in these groups was 17.2 months (95% CI 16.3–18.1) and 11.5 months (95% CI 11.0–12.0), respectively. In Cox regression analysis, primary tumor resection was significantly associated with improved overall survival (hazard ratio of death = 0.44 [95% CI 0.35–0.55], p < 0.001). This large population‐based study shows an overall survival benefit for patients with incurable stage IV CRC who underwent primary tumor resection as the initial treatment after diagnosis, compared to patients who started systemic therapy with the primary tumor in situ. This result is an argument in favor of resection of the primary tumor, even when patients have little to no symptoms.
- 24 June 2016
- Published by Wiley in International Journal of Cancer
- Vol. 139 (9) , 2082-2094
Open AccessPalliative resection of the primary tumor is associated with improved overall survival in incurable stage IV colorectal cancer: A nationwide population‐based propensity‐score adjusted study in the Netherlands
As the value of palliative primary tumor resection in stage IV colorectal cancer (CRC) is still under debate, the purpose of this population‐based study was to investigate if palliative primary tumor resection as the initial treatment after diagnosis was associated with improved overall survival. All patients with stage IV colorectal adenocarcinoma (2008–2011) were selected from the Netherlands Cancer Registry, and patients undergoing treatment with curative intent (i.e., metastasectomy, radiofrequency ablation and/or hyperthermic intraperitoneal chemotherapy), or best supportive care were excluded. After propensity score matching, a multivariable Cox proportional hazard model was performed to determine the association between treatment strategy and mortality. From a total group of 10,371 patients with stage IV CRC, 2,746 patients (26%) underwent an elective palliative resection of the primary tumor, whether or not followed by systemic therapy, and 3,345 patients (32%) were initially treated with palliative systemic therapy. After propensity score matching, median overall survival in these groups was 17.2 months (95% CI 16.3–18.1) and 11.5 months (95% CI 11.0–12.0), respectively. In Cox regression analysis, primary tumor resection was significantly associated with improved overall survival (hazard ratio of death = 0.44 [95% CI 0.35–0.55], p < 0.001). This large population‐based study shows an overall survival benefit for patients with incurable stage IV CRC who underwent primary tumor resection as the initial treatment after diagnosis, compared to patients who started systemic therapy with the primary tumor in situ. This result is an argument in favor of resection of the primary tumor, even when patients have little to no symptoms.
- 1 September 2015
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 41 (9) , 1217-1225
Large variation in the utilization of liver resections in stage IV colorectal cancer patients with metastases confined to the liver
- 1 September 2015
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 41 (9) , 1217-1225
Large variation in the utilization of liver resections in stage IV colorectal cancer patients with metastases confined to the liver
- Open Access
- 2 October 2014
- Published by Springer Nature in BMC Cancer
- Vol. 14 (1) , 1-7
The CAIRO4 study: the role of surgery of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastases of colorectal cancer – a randomized phase III study of the Dutch Colorectal Cancer Group (DCCG)
There is no consensus regarding resection of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastatic colorectal cancer (CRC). A potential benefit of resection of the primary tumour is to prevent complications of the primary tumour in later stages of the disease. We here propose a randomized trial in order to demonstrate that resection of the primary tumour improves overall survival. The CAIRO4 study is a multicentre, randomized, phase III study of the Dutch Colorectal Cancer Group (DCCG). Patients with synchronous unresectable metastases of CRC and few or absent symptoms of the primary tumour are randomized 1:1 between systemic therapy only, and resection of the primary tumour followed by systemic therapy. Systemic therapy will consist of fluoropyrimidine-based chemotherapy in combination with bevacizumab. The primary objective of this study is to determine the clinical benefit in terms of overall survival of initial resection of the primary tumour. Secondary endpoints include progression free survival, surgical morbidity, quality of life and the number of patients requiring resection of the primary tumour in the control arm. The CAIRO4 study is a multicentre, randomized, phase III study that will assess the benefit of resection of the primary tumour in patients with synchronous metastatic CRC. The CAIRO4 study is registered at clinicaltrials.gov ( NCT01606098 )
- 2 October 2014
- Published by Springer Nature in BMC Cancer
- Vol. 14 (1) , 1-7
Open AccessThe CAIRO4 study: the role of surgery of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastases of colorectal cancer – a randomized phase III study of the Dutch Colorectal Cancer Group (DCCG)
There is no consensus regarding resection of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastatic colorectal cancer (CRC). A potential benefit of resection of the primary tumour is to prevent complications of the primary tumour in later stages of the disease. We here propose a randomized trial in order to demonstrate that resection of the primary tumour improves overall survival. The CAIRO4 study is a multicentre, randomized, phase III study of the Dutch Colorectal Cancer Group (DCCG). Patients with synchronous unresectable metastases of CRC and few or absent symptoms of the primary tumour are randomized 1:1 between systemic therapy only, and resection of the primary tumour followed by systemic therapy. Systemic therapy will consist of fluoropyrimidine-based chemotherapy in combination with bevacizumab. The primary objective of this study is to determine the clinical benefit in terms of overall survival of initial resection of the primary tumour. Secondary endpoints include progression free survival, surgical morbidity, quality of life and the number of patients requiring resection of the primary tumour in the control arm. The CAIRO4 study is a multicentre, randomized, phase III study that will assess the benefit of resection of the primary tumour in patients with synchronous metastatic CRC. The CAIRO4 study is registered at clinicaltrials.gov ( NCT01606098 )